Merck & Co. Inc.
MRKEquityAI Summary
Updated 18h ago
Merck & Co
Merck & Co. Inc. (MRK) is showing an interesting divergence. Price has pulled back — extension indicators are in the lower portion of their historical range — but buying pressure is holding up. Flow indicators remain above average despite the price weakness. For reference: Flow Score 29/100, Trend & Momentum Score 22/100.
Market Positioning
What's Happening
Merck sets FY 2026 sales guidance at $65.5-67B
On April 9, 2026, Merck provided full-year 2026 earnings guidance, projecting sales between $65.5 billion and $67.0 billion. This signals confidence in sustained pharma and vaccine demand despite patent cliffs -- most overlook how animal health's 9.8% revenue share cushions volatility. Company guidance positions MRK for mid-single-digit growth.
The Bigger Picture
MRK navigates pharma patent cliffs and oncology dominance
Keytruda revenue engine pressures
Keytruda drives 73.9% of pharma sales, but looming patent expiration creates revenue risks -- second-order effects hit margins if biosimilars flood in. Merck's FY 2026 sales guidance of $65.5-67 billion per company guidance assumes offset via vaccines at 15.5% and animal health at 9.8%. Competitive landscape intensifies with rivals chasing PD-1 dominance.
Upcoming Catalysts
Updated 6d agoMerck reports Q1 results pre-market with 9:00 a.m. ET call -- watch for FY 2026 guidance update on $65.5-67B sales and Keytruda trends versus $15.91B revenue consensus.
Technical Analysis
Market Positioning
Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.
Key Levels
Looking at the full picture for Merck & Co. Inc. (MRK): extension is below average (29th percentile), momentum is deeply below average — at historically low levels (8th percentile), flow is neutral (54th percentile), volatility is slightly above average (59th percentile). This is an interesting combination. Extension and momentum are both at historically low levels — price is compressed and has lost upward energy — while flow indicators remain steady. This pattern, where price has weakened but buying pressure is holding, has historically been associated with periods that resolved to the upside more often than not. That said, it is not a prediction — it is context.
Where is money flowing?
Trend
Is momentum building or fading?
What is the relative strength?
How extended is this move?
Where are the key levels?
What risk am I taking?
Conclusion
Merck & Co. Inc. (MRK) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme level that defines the current setup strongly in either direction. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.
Your portfolio. Your context. Smarter decisions.
Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.
Personalized insights based on your actual holdings
Major market movements delivered to your inbox
Track the assets that matter most to you
No credit card required